News from the FDA/CDC

U.S. adults reach Healthy People 2020 cholesterol goal


 

Good news: High cholesterol is down in the United States. More good news: Low HDL cholesterol is down in the United States.

The prevalence of high total cholesterol in adults aged 20 years and older dropped from 18.3% in 1999-2000 to 10.5% in 2017-2018. And starting in 2007-2008, the prevalence of low HDL cholesterol declined from 22.2% to 16.0% in 2017-2018, the National Center for Health Statistics reported.

HDL cholesterol data before 2007 were not presented because of changes in laboratories and methods, but both trends are significant, and the decline in high total cholesterol means that the Healthy People 2020 goal of dropping prevalence to 13.5% has been met, said Margaret D. Carroll, MSPH, and Cheryl D. Fryar, MSPH, of the NCHS.

The demographic details, however, show some disparities hidden by the broader measures. The prevalence of low HDL cholesterol for women in 2015-2018 was 8.5%, but for men it was 26.6%, the NCHS investigators said.

And that Healthy People 2020 goal for total cholesterol? Age makes a difference: 7.5% of adults aged 20-39 years had high total cholesterol in 2015-2018, as did 11.4% of those aged 60 years and older, but those aged 40-59 years had a significantly higher prevalence of 15.7%, they reported.

Race/ethnicity was also a factor. Prevalence of low HDL was similar for white (16.6%) and Asian (15.8%) adults in 2015-2018, but black adults’ low HDL prevalence was significantly lower (11.9%) and Hispanics’ was significantly higher (21.9%), the researchers said.

The analysis was based on data from the National Health and Nutrition Examination Survey. The investigators defined high total cholesterol as a level of 240 mg/dL or more, and low HDL cholesterol as less than 40 mg/dL. LDL cholesterol was not included in the analysis.

Recommended Reading

PCSK9 inhibitors unexpectedly link with lower VTE, aortic stenosis
MDedge Cardiology
Substantial very late MACE risk after PCI for SIHD
MDedge Cardiology
FOURIER: Evolocumab follow-up shows no cognitive adverse effects
MDedge Cardiology
Adolescent obesity, diabetes linked to atherosclerotic signs
MDedge Cardiology
More from REDUCE-IT: Icosapent ethyl cuts revascularization by a third
MDedge Cardiology
Patients find CAC more persuasive than ASCVD risk score for statin decisions
MDedge Cardiology
Latest from ISCHEMIA: Worse outcomes in patients with intermediate left main disease on CCTA
MDedge Cardiology
Ticagrelor gets FDA nod for DAPT in high-risk patients with CAD
MDedge Cardiology
RA raises cardiac risk even without CAD
MDedge Cardiology
CAC scoring pinpoints stenoses in asymptomatic diabetes patients
MDedge Cardiology